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BACKGROUND: In October 2015, the Organ Procurement and Transplantation Network 
(OPTN) implemented a revised liver exception point policy to address the disparity 
between Hepatocellular Carcinoma (HCC) and non-HCC patients in access to deceased-
donor liver transplant (DDLT). Under the new policy, HCC patients obtain exception 
points only after 6 months on the waitlist. The impact of this policy change on access to 
DDLT and waitlist mortality for HCC and non-HCC patients has not been described. 
 
METHODS: Using Scientific Registry of Transplant Recipients (SRTR) data on 29,759 
adult, first-time DDLT waitlist registrants from 2014 to 2016, we compared access to 
DDLT and mortality risk in HCC vs. non-HCC patients, pre-implementation (10/8/2014-
10/7/2015) and post-implementation (10/8/2015-6/30/2016). Waitlist dropout due to 
deteriorating condition was classified as mortality. We estimated cumulative incidence of 
DDLT accounting for the competing risk of waitlist mortality overall and for four different 
strata of calculated MELD (6-10, 11-18, 19-24, and 25-40). We used Cox regression to 
model cause-specific hazard, and Fine and Gray methods to model mortality accounting 
for the competing risk of transplantation, adjusting for age, gender, race, and time-varying 
calculated MELD. 
 
RESULTS: During the pre-implementation period, HCC patients had 5-fold higher access 
to DDLT than non-HCC patients (aCSHR = 5.32 5.61 5.91, p<0.001). During the post-
implementation period, HCC and non-HCC patients had comparable chances of receiving 
iii 
 
DDLT experiencing access to DDLT (aCSHR = 0.81 0.93 1.07, p>0.1). After accounting for 
the reduction in mortality due to transplant in both groups, risk of waitlist mortality/dropout 
for HCC candidates compared to non-HCC candidates increased from 1.3-fold higher risk 
of waitlist mortality/dropout pre-implementation (asHR =1.15 1.30 1.46, p=0.005) to 2.18-
fold higher risk of waitlist mortality/dropout post-implementation (aSHR = 1.69 2.18 2.80, 
p<0.001).  
 
CONCLUSIONS: The October 2015 HCC exception policy change eliminated the 
disparity in access to DDLT between HCC and non-HCC patients. However, risk of waitlist 
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Hepatocellular carcinoma (HCC) is primary malignancy of the liver resulting from the 
abnormal growth of hepatocytes. Major risk factors for developing HCC include hepatitis 
B virus (HBV) or hepatitis C virus (HCV) infection, heavy alcohol consumption, chronic 
liver disease, and cirrhosis (1). Obesity (2, 3), non-alcoholic fatty liver disease (1, 4), and 
diabetes (3, 5) have also been found to be associated with development of HCC.  
 
Global epidemiology of HCC 
Globally, the burden of HCC varies according to geographic region, occurring 
predominantly in men and following the distribution of endemic HBV infection (6). 
According to the Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2012, 
HCC was the fifth most common cancer among men and ninth most common cancer in 
women, representing 7.5% (554,000 cases) of all male cancer cases and 3.4% (228,000 
cases) of all female cancer cases. In 2012, HCC was the second most common cause of 
cancer-related death worldwide with an estimated 746,000 deaths (including male and 
female). Altogether, 9.1% of all cancer deaths in the world occur due to HCC, with the 
highest incidence of and mortality due to HCC occurring in Eastern Asia for both men and 
women. In 2012, the estimated age-standardized incidence rate of HCC for men in Eastern 
Asia was about 31.96 per 100,000 persons per year, while for women the estimated age-
standardized incidence rate was about 10.02 per 100,000 persons per year. The estimated 
age-standardized rates of mortality due to HCC for men and women in Eastern Asia were 




Epidemiology of HCC in the United States 
According to the 2013 Surveillance, Epidemiology, and End Results (SEER), HCC is 
relatively rare in the United States. Based on reported cases in 2009-2013, the age-adjusted 
incidence rate of combined liver and bile duct cancer is 8.4 per 100,000 per year. In 2016, 
there were an estimated 39,230 new liver and bile duct cancer cases, representing 2.3% of 
all new cancer cases. However, the incidence rate has increased by 3% per year over the 
last ten years (8). Between 2000 and 2010, HCC incidence increased by 5.4% per year 
(2000-2007) and then 2.3% per year (2007-2010). The rate of increase was highest among 
persons aged 50-64 years. Between 2000 and 2010, there was also a rising of HCC 
incidence rate among white, black and Hispanic persons, while HCC incidence among 
Asians/Pacific Islanders showed a decreasing trend from 2002 to 2010. Overall age and 
race-specific incidence rates are higher among men compared to women (9). 
 
Mortality of HCC in the United States 
Based on 2009-2013 cancer deaths, the combined age-adjusted mortality rate for liver and 
bile duct cancer in the United States is 6.1 per 100,000 persons per year. In 2016, there 
were an estimated 27,170 deaths due to liver and bile duct cancer representing about 4.6% 
of all cancer deaths. The mortality rate for liver and bile duct cancer has been increasing 
by 2.5% per year for the last decade. Based on 2006-2012 SEER data, only 17.5% of liver 
and bile duct cancer patients survived 5 or more years after being diagnosed. However, if 
diagnosed at a localized stage, about 43% of liver and bile duct cancer patients survived 5 
or more years after being diagnosed (8). In a study conducted using 1992-2005 SEER data, 
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age-adjusted mortality rates due to liver and bile duct cancer were found to be the highest 
among Asians/Pacific Islanders in the 35-49 and 65+ age groups (9). The same study 
showed that among those in the 50-65 age group, mortality was highest in Black, followed 
by Hispanics, Asians/Pacific Islanders, and Whites. Mortality rate also differs by state, 
ranging from 2.3-6.8 per 100,000 people with the highest mortality rate in Washington, 
DC and gulf coast states (5.6-5.8 per 100,000 people) (9). Between 2000 and 2010, 
mortality rate increased among persons aged 50-64 years in most states while it either 
decreased or remained constant among those aged 35-49 years (9).  
 
Treatment options for HCC  
Treatment selection for HCC depends primarily on the size, severity, and distribution of 
the underlying tumor and on the patient’s physical condition. Tumor resection and liver 
transplantation are potentially curative treatment options for HCC (10, 11). Other treatment 
options for early HCC include radiofrequency ablation, microwave ablation, percutaneous 
ethanol injection (PEI), and percutaneous acetic acid injection (PAI). For intermediate and 
advanced stage HCC, treatment options are trans-arterial chemoembolization (TACE) and, 
in some cases, systemic chemotherapy (10-12). 
 
Orthotopic liver transplantation 
Orthotopic liver transplantation (OLT) is usually suitable for early stage HCC patients with 
either a single lesion ≤5cm, or ≤3 nodules, each ≤3cm without any vascular or extrahepatic 
spread (10, 12). Several studies reported recurrence-free survival following OLT, and, in 
most cases, overall survival is better for liver transplant recipients compared to patients 
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undergoing surgical resection (10, 13, 14). A study of 11,187 HCC cases, using 2001-2009 
SEER data, found that mortality within 2 years of HCC diagnosis for the surgical resection 
(N=2150) group was 44%, while it was only 29% for the liver transplant (N=296) group 
(p<0.001) (10) 
Liver transplantation in the United States 
In the United States, liver transplantation is performed using both living donors (LDLT) 
and deceased donors (DDLT). In 2012, a meta-analysis reported similar one, three and five 
year survival and recurrence rates of HCC for LDLT and DDLT recipients (15). However, 
controversy remains regarding the relative advantages of LDLT and DDLT (16, 17). 
Nevertheless, in the US more than 95% of OLT are DDLT (18, 19). Due to ethical debate 
regarding donor health, adult LDLT continues to be stagnant (19). Saidi et al. used data 
reported to the United Network for Organ Sharing (UNOS) to conduct a study of 6,028 
HCC candidates who underwent LT (5,858 DDLT and 170 LDLT) between 1990 and 2009. 
In this study, there was an increase in the number of DDLT cases from 337 (2.3%) in 2002 
to 1,142 (8.75%) in 2009 (p<0.001) among HCC candidates. In contrast, the number of 
LDLT cases among HCC candidates was similar, decreasing slightly from 16 (5.7%) in 
2002 to 14 in 2009 (5.7%) (p=0.1) (20). According to the 2015 SRTR annual report, 6,768 
of 7,127 adult LT procedures in 2015 were DDLT (21).  
 
Development of allocation system for DDLT 
In the United States there are 140 liver transplant centers, each of which is affiliated with 
a local organ procurement organization (OPO) (22). Each OPO is connected with one to 
eight transplant centers and is responsible for retrieving, preserving, and transporting donor 
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livers to regional liver transplant centers (22). Due to a constant organ shortage, a system 
was developed to prioritize the patients waiting for donor organs (22). Before 1997, 
waitlisted transplant candidates were stratified according to their hospital status (ICU 
patients, non-ICU hospitalized patients, ambulatory outpatient). Within each stratum, 
patients were prioritized according to their accrued waiting time. In 1998, a new allocation 
system was developed to classify transplant candidates as status 1, status 2A, status 2B, 
and status 3 based on their hospital status, Child-Turcotte-Pugh (CTP) score, and presence 
of sequelae of end stage liver disease (22). Child-Turcotte-Pugh (CTP) score is calculated 
from clinical and biochemical parameters and the total score was used to classify each 
patient as CTP class A (5-6 points), B (7-9 points), or C (≥10 points) (22). Within each 
stratum, candidates were again ranked according to accrued waiting time (22). As such, 
some patients with less medical urgency could have higher priority to receive a donor liver 
than patients with heightened medical urgency on the basis of longer accumulated waiting 
time (22). In addition, this system was highly dependent on subjective clinical assessment 
from physicians, which cannot be standardized (22).  
 
The Model for End-Stage Liver Disease (MELD) score  
Liver allocation policy was changed on February 27, 2002, granting priority to waitlisted 
candidates based only on their medical urgency as determined by the Model for End-Stage 
Liver Disease (MELD) score as opposed to on accrued waiting time (22). MELD score is 
a reliable measure of short-term mortality risk for patients with liver failure (27) which is 
calculated from serum bilirubin, serum creatinine, and international normalized ratio (INR) 




Factors related to DDLT 
Using data from the Scientific Registry of Transplant Recipients (SRTR), a study, 
conducted on 57,503 adult waitlisted transplant candidates from 2002 to 2008, reported 
that blood group, and donation service area (the geographic area served by single OPO) 
were associated with access to DDLT (24). According to the findings of this study, 
candidate age, height, diagnosis, hospitalization, and combined liver-intestine or liver-
kidney listing were associated with higher rates of DDLT (24). In contrast, female sex, 
higher serum creatinine (S. Cr), higher bilirubin, dialysis, and prior liver transplant were 
associated with lower rates of DDLT (24). In another study using 2002-2007 SRTR data, 
Black transplant candidates were found to have similar access to DDLT compared to white 
candidates, while Hispanic and Asian candidates had lower rates of DDLT compared to 
white transplant candidates (25).  
 
Eligibility criteria for HCC Liver transplantation candidates 
In 1996, Mozzafero et al. studied the outcomes of 48 cirrhosis patients with HCC who 
underwent OLT and found overall and recurrence-free survival at four years post-OLT to 
be 85% and 92% respectively for HCC patients with small tumors inside the Milan criteria 
(single nodule ≤5 cm; up to three nodules ≤3cm; and without macrovascular invasion or 
extra hepatic disease) (26). However, in cases in which the tumor exceeded the parameters 
specified by the Milan criteria, overall and recurrence-free survival rates decreased to 50% 
and 59% respectively (26). A later single center study of 489 HCC patients undergoing 
liver transplantation between 1985 and 2003 reconfirmed the bad prognosis following OLT 
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for HCC patients with tumors falling outside the Milan criteria (27). In 1998, the Organ 
Procurement and Transplantation Network (OPTN) adopted the Milan criteria and 
considered HCC candidates fulfilling these criteria to be eligible for DDLT (28). 
 
Liver allocation system for eligible HCC candidates  
HCC candidates who meet the Milan criteria usually have low MELD scores since 
underlying liver functions are often well preserved in these patients (22). Thus, if HCC 
candidates are only evaluated for transplant according to their calculated MELD scores, 
they will endure long waiting times prior to transplantation. During this time, HCC 
candidates’ tumors will either grow larger or spread to other parts of the body, making 
these candidates ineligible for transplant (outside of Milan criteria). Therefore, the chances 
of waitlist mortality/dropout are heightened for HCC candidates if they are assessed only 
by their calculated MELD scores (22). To establish a fair chance of liver allocation for 
HCC candidates and to avoid higher rates of waitlist dropout, HCC candidates are granted 
MELD exception points equivalent to certain MELD scores from the beginning of the 
MELD era (29). This change results in higher DDLT rate, shorter median time to DDLT, 
and lower dropout rate for HCC candidates compared to the previous era (28).  
 
Modification of policy regarding exception score for HCC candidates 
To increase the efficiency of the organ allocation system and to establish an equity between 
HCC and non-HCC candidates, the policy regarding standardized MELD exception scores 
was modified on several occasions, the first of which occurred in 2002 (Table 1) (30). In 
2005, the exception point policy was revised such that HCC candidates fulfilling the Milan 
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criteria automatically received MELD scores of 22, 25, and 28 during initial application, 
first extension (3 months) and second extension (6 months), respectively (31).  
 
Disparity in access to DDLT  
Even after changing the initial exception point from 24 to 22, there was concern about 
disparities in organ allocation for HCC candidates compared to non-HCC candidates (32, 
33). A study by Sharma et al. reported that HCC candidates had a 26% higher chance of 
getting transplanted compared to non-HCC patients (24, 34). In addition, non-HCC 
candidates also had higher rates of waitlist mortality/dropout compared to HCC exception 
patients at 30 (6% vs 1.8%), 60 (8.4% vs 3.6%), 90 (10.2% vs. 5.1%), 180 (13.6% vs. 
8.6%) and 365 (17.7% vs. 11.5%) days (32, 34). The odds of waitlist dropout were also 
significantly higher among non-HCC candidates compared to HCC candidates (33, 35, 36). 
Additionally, the risk of waitlist removal increased over time for non-HCC candidates, but 
remained stable for HCC candidates (33).  
 
Revised policy for exception point allocation in October 2015 
To reduce the disparity in access to DDLT between HCC and non-HCC candidates, OPTN 
changed the policy regarding MELD exception points again in October 2015. Under the 
new policy, HCC candidates who meet the Milan criteria acquire a first exception score of 
28 six months after their initial exception point application (37). Under this policy, HCC 
candidates are registered at their calculated MELD scores during initial application for 
exception points and also at first extension (3 months) (37). The October 2015 exception 
point policy also states that the exception point will be capped at 34 for all candidates. For 
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candidates who already had MELD exception scores of 35-40, it would also be capped at 
34 (31, 37, 38).  
 
Study rationale and objectives 
To assess the effectiveness of the revised MELD exception point policy (October 2015), 
OPTN’s public comment proposal suggested a pre- vs. post-policy implementation 
analysis at six-month intervals with fixed metrics, including waitlist outcomes (probability 
of removal for transplant, mortality, dropout due to deteriorating condition) for approved 
requests (39). In response to the OPTN proposal, and to address the question of changes in 
access to DDLT for HCC and non-HCC patients following the recent policy change, we 
conducted a retrospective cohort study using national registry data to estimate the 
association between access to transplant and HCC in both the pre-policy-implementation 
and post-policy-implementation periods. We also explored the risk of waitlist mortality or 
dropout for HCC and non-HCC candidates before and after the policy change.  
The findings from this study will inform the OPTN/UNOS Liver and Intestinal Organ 
Transplantation Committee as to whether the new policy achieves the desired equity in 






This study used data from the Scientific Registry of Transplant Recipients (SRTR). The 
SRTR data system includes data on all donors, waitlisted candidates, and transplant 
recipients in the US, submitted by the members of the Organ Procurement and 
Transplantation Network (OPTN), and has been described elsewhere (40, 41). The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human 
Services provides oversight to the activities of the OPTN and SRTR contractors. 
This study utilized de-identified data and has been exempted by the Johns Hopkins School 
of Medicine Institutional Review Board (study number NA_00042871). 
 
Study population 
Our study population consisted of 29,249 adult first-time transplant candidates prevalently 
listed for DDLT at any time between October 8, 2014 and July 1, 2016. We excluded 
candidates who first became active on the waitlist before January 1, 2007 to prevent any 
possible effects of different organ allocation policies on access to transplantation. We also 
excluded live donor recipients and patients who were ever classified as Status 1 (Figure 1).  
 
Person-time  
Time of origin for waitlisted candidates was their date of enrollment for this study (the later 
of their first date of waitlist registration or October 8, 2014). All waitlisted candidates were 
either administratively censored on July 31, 2016 or removed due to transplant, waitlist 
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mortality/dropout, or censored if removed from the waitlist for reasons such as transfer to 
another center, transplant at a different center, or improved condition.  
 
Outcome ascertainment  
The primary outcome of this study was DDLT, which was ascertained from the SRTR 
registry. Patient mortality was ascertained from SRTR and supplemented with linkage to 
the Social Security Death Master File. Removal from the waitlist due to deteriorating 
condition (dropout) was treated as equivalent to waitlist mortality. 
 
Exposure ascertainment 
Hepatocellular carcinoma: Candidates were considered to have hepatocellular carcinoma 
(HCC) if they received a MELD exception point for HCC. Candidates with no MELD 
exception and who did not have a diagnosis of HCC were regarded as non-HCC candidates. 
Candidates with a diagnosis of HCC who did not receive a MELD exception (N=1097), or 
who received a MELD exception but who had no diagnosis of HCC (N=382), were 
excluded from analysis. 
 
Policy era: The change in allocation policy for DDLT with regards to MELD exception 
points was implemented on October 8, 2015. We therefore divided transplant candidates 
in our study population into two eras: pre-implementation (October 8, 2014 to October 7, 
2015) and post-implementation (October 8, 2015 to July 31, 2016). HCC patients who 
applied for MELD exception during the pre-implementation era, and non-HCC patients 
who entered the study during the pre-implementation era, were classified as "pre-
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Model of End-stage Liver Disease (MELD) score: MELD score for each individual was 
calculated from the laboratory values of creatinine, bilirubin, and INR (42) and was 
designated “calculated MELD (cMELD)” for this study. We also used “allocation MELD 
(aMELD)” to denote MELD score that was used to decide a candidate’s priority for liver 
allocation. In nonexception cases, allocation MELD and calculated MELD had the same 
value. For exception cases, allocation MELD was the larger of calculated MELD or 
exception MELD. MELD score was treated as time-varying due to variation in MELD 
score over time depending on a candidate’s physical condition. Candidates who were 
temporarily inactive on the waitlist were not excluded from the primary analysis since they 
were still at risk for death. 
 
Age and race: Age was dichotomized as 18-49 years and >50 years, based on Martingale 
residual plots. Race was categorized as non-Hispanic White, non-Hispanic Black, 
Hispanic, and Other.  
 
Statistical analysis 
Descriptive analysis: All statistical analyses were performed using Stata 14.2 for Linux 
(Stata Corp., College Station, TX). HCC and non-HCC candidates were compared using 
chi-squared and Fisher’s exact tests for categorical variables and unpaired t-tests or 
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Wilcoxon rank sum tests for continuous variables with normal or non-normal distributions 
respectively. Comparisons between HCC and non-HCC candidates were made separately 
for both eras. All tests were two-sided, and a p-value of ≤0.05 was considered statistically 
significant. Confidence intervals were reported as per the method of Louis and Zeger (4). 
Cumulative incidence of waitlist mortality/dropout and transplantation: Cumulative 
incidence of DDLT accounting for the competing risk of waitlist mortality/dropout was 
estimated for each era as described by Coviello et al. (43); for each era, we estimated the 
cumulative incidence of DDLT overall and for each of four different strata of calculated 
MELD (6-10, 11-18, 19-24, and 25-40). Cumulative incidence of waitlist mortality/dropout 
accounting for the competing risk of DDLT was estimated using the same techniques. 
 
Transplant rates for HCC and non-HCC patients pre- and post-policy change: We used a 
Cox proportional hazards model to compare rates of DDLT among HCC versus non-HCC 
patients, both pre- and post-policy change, adjusting for age, gender, race, and calculated 
MELD. This model treated the competing event as a censored observation and did not 
assume independence between the two events. Thus, cause specific hazard ratio (CSHR)  
provides only the association between the exposure and the outcome and should not be 
interpreted directly as a cumulative incidence function (44). Similarly, we conducted a 
competing risk analysis using the Fine and Gray method (45) to account for the fact that 
waitlist mortality/dropout prevents access to DDLT.  
 
Waitlist mortality/dropout for HCC and non-HCC patients, accounting for the competing 
risk of transplantation: We compared mortality/dropout for HCC versus non-HCC 
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patients, accounting for the competing risk of transplant, pre- and post-policy 
implementation using the Fine and Gray method (45). This method models subdistribution 
hazard ratio (sub-HR) for both events between HCC and non-HCC candidates after 
accounting for the fact that the two events preclude each other. In this method, candidates 
were not censored even if they had the competing event and were allowed direct modeling 
of sub-distribution cumulative incidence function (CIF) (44). Competing risks analyses 
were performed for the entire cohort, and stratified by MELD category as described above. 
We also constructed a separate model using Cox regression to compare rates of waitlist 
mortality/dropout among HCC versus non-HCC patients. 
 
Sensitivity analysis 
Although candidates who were temporarily inactive on the waitlist were at risk of 
mortality, they were not considered eligible for DDLT. Therefore, we excluded candidates 
who were inactive on the waitlist at any point during the study period and ran the same 






During the pre-implementation era, 4,716 of 21,984 candidates (21.4%) had HCC 
compared to 2,084 of 7,775 candidates (26.8%) during the post-implementation era. 
Compared to non-HCC candidates in both eras, HCC candidates were older (median (IQR) 
age 61 (57-65) years vs. 57 (57-65) years, p<0.001), and were more likely to be male (76% 
vs. 59%, p<0.001). The racial distribution was similar in both eras and most HCC and non-
HCC waitlist candidates were white (pre-implementation 63% vs. 72.4%, p<0.001; post-
implementation 64% vs. 71.9%, p<0.001). Among HCC and non-HCC candidates during 
both periods, blood type O was the most common (pre-implementation 47.3% vs. 46.5%; 
post-implementation 46.8% vs. 47.0%) (Table 2).  
At baseline, HCC candidates had median calculated MELD of 10 (IQR 8-14) in both eras. 
Pre-implementation, median calculated MELD among non-HCC candidates was 15 (IQR 
11-20), while post-implementation, median calculated MELD among non-HCC candidates 
was 19 (IQR 14-26). In the pre-implementation era, allocation MELD was higher for HCC 
candidates compared to non-HCC candidates (median (IQR) aMELD 22 (22-25) vs. 16 
(11-22), p<0.001). However, in the post-implementation era, allocation MELD was 
significantly lower among HCC candidates compared to non-HCC candidates (median 
(IQR) aMELD 11 (8-15) vs. 20 (15-28), p<0.001). Hepatitis C cirrhosis (pre-
implementation 39.6% vs post-implementation 35.9% ), hepatoma with cirrhosis (pre-
implementation 19.5% vs post-implementation 21.9%), alcoholic cirrhosis (pre-
implementation 11.7% vs post-implementation 12.9%), and hepatoma without cirrhosis 
(pre-implementation 12.1% vs post-implementation 10.7%) were the most common 
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primary diagnoses for HCC candidates regardless of the policy era. Alcoholic cirrhosis 
(pre-implementation 30.3% vs post-implementation 33.7%), fatty liver disease (pre-
implementation 15.3% vs post-implementation 20.2% ), and hepatitis C cirrhosis (pre-
implementation 22.4% vs post-implementation 13.1% ) were the most common primary 
diagnoses for non-HCC waitlist candidates.  
 
Access to DDLT  
During the pre-implementation era, the incidence of DDLT was 35.7% among HCC 
candidates compared to 18.7% among non-HCC candidates. Conversely, during the post-
implementation era, the incidence of DDLT was 42.7% among non-HCC candidates 
compared to 11.2% among HCC candidates (Figure 2). 
 
Access to DDLT across MELD strata 
Pre-implementation, the incidence of DDLT at 6 months was higher among HCC 
candidates compared to non-HCC candidates in calculated MELD strata 6-10 (29.5 % vs. 
0.59%), 11-18 (30.8 % vs. 4.5%), and 19-24 (22.2% vs. 12.9%). In calculated MELD 
stratum 25-40, HCC candidates had lower access to DDLT compared to non-HCC 
candidates (32.8% vs. 44.3%) (Figure 3).  
 
Post-implementation, HCC and non-HCC candidates had similar incidence of DDLT at 6 
months in calculated MELD strata 6-10 (5.1% vs. 3.7%) and 11-18 (12.0% vs. 15.8%). 
However, HCC candidates had lower incidence of DDLT compared to non-HCC 
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candidates in calculated MELD strata 19-24 (13.3% vs. 33.7%) and 25-40 (67.0% vs. 
27.4%) (Figure 4). 
 
Waitlist mortality/dropout 
Among all transplant candidates, HCC candidates had slightly lower incidence of waitlist 
mortality/dropout compared to non-HCC candidates in both eras (pre-implementation 6% 
vs. 9%; post implementation 6% vs. 10%) (Figure 5). 
 
Waitlist mortality/dropout across MELD strata 
Pre-implementation, incidence of waitlist mortality/dropout was higher among HCC 
candidates compared to non-HCC candidates in MELD strata 6-10 (3.1% vs. 1.3%), 11-18 
(5.7% vs. 3.5%), 19-24 (11.0% vs. 5.7%) and 25-40 (25% vs. 19.9%) (Figure 6).  
Post-implementation, incidence of waitlist mortality/dropout was 1.64% for both HCC and 
non-HCC candidates in MELD stratum 6-10. However, HCC candidates had slightly 
higher incidence of waitlist mortality/dropout in MELD strata 11-18 (5.8% vs. 3.9%) and 
19-24 (9.8% vs. 5.8%). In MELD stratum 25-40, waitlist mortality/dropout was 44.5% 
among HCC candidates versus 21.8% among non-HCC candidates (Figure 7). 
 
HCC and DDLT rate pre-and post-implementation 
In an adjusted model, access to DDLT was 5-fold higher for HCC candidates compared to 
non-HCC candidates during the pre-implementation period (aCSHR = 5.32 5.61 5.91, 
p<0.001) (Table 3). During the post implementation era, there was no evidence of a 
difference in access to DDLT among HCC and non-HCC candidates (aCSHR= 0.81 0.93 
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1.07, p>0.1). The change in association between HCC and access to DDLT from pre-
implementation to post-implementation was statistically significant (interaction p<0.001) 
(Table 3).  
Waitlisted candidates older than 50 years of age had 1.11 fold higher access to DDLT 
compared to candidates aged 18-50 (aCSHR = 1.06 1.11 1.17, p<0.001). Female candidates 
had 18% lower access to DDLT compared to male candidates (aCSHR = 0.79 0.82 0.86, 
p<0.001). Compared to white candidates, Black candidates had similar access to DDLT 
(aCSHR = 0.90 0.97 1.04, p>0.1). However, compared to white candidates, Hispanic 
candidates and those of other races had 35% (aCSHR = 0.61 0.65 0.69, p<0.001) and 19% 
lower access to DDLT (aCSHR = 0.74 0.81 0.89, p<0.001) respectively. Access to DDLT for 
waitlisted candidates was 2.25 fold higher with 5 points increase in calculated MELD 
scores (aCSHR = 2.23 2.25 2.28, p<0.001) (Table 3). Table-3 also showed the result from the 
competing risk model. 
 
HCC and DDLT rate across MELD strata 
Calculated MELD 6-10: Pre-implementation, HCC candidates had 114.49 fold greater 
access to DDLT compared to non-HCC candidates after adjusting for age, gender, race, 
and calculated MELD (aCSHR = 82.26 114.49 159.35, p <0.001). Post-implementation, the 
association between HCC and access to DDLT persisted, but was attenuated to only 2.91 
fold higher access to DDLT for HCC candidates compared to non-HCC candidates 
(aCSHR = 1.64 2.91 5.18, p<0.001). The difference in pre- and post-implementation 
association between HCC and access to DDLT was statistically significant (interaction 




Calculated MELD 11-18: Pre-implementation, HCC candidates had 10.70 fold higher 
access to DDLT compared to non-HCC candidates (aCSHR = 9.67 10.70 11.83, p<0.001). 
Post-implementation, HCC and non-HCC candidates had similar access to DDLT (aCSHR 
= 0.75
 
0.94 1.18, p >0.1). The difference in pre- and post-implementation association between 
HCC and access to DDLT was statistically significant (interaction p<0.001) (Table 5).  
 
Calculated MELD 19-24: Pre-implementation, HCC candidates had 2.18 fold higher 
access to DDLT compared to non-HCC candidates (aCSHR = 1.85 2.18 2.57, p<0.001). Post-
implementation, access to DDLT was attenuated for HCC candidates compared to non-
HCC candidates: HCC candidates had 61% lower access to DDLT compared to non-HCC 
candidates (aCSHR = 0.27 0.39 0.58, p<0.001). The difference in pre- and post-
implementation association between HCC and access to DDLT was statistically significant 
(interaction p<0.001) (Table 5). 
 
Calculated MELD 25-40: Pre-implementation, HCC candidates had 42% lower access to 
DDLT than non-HCC candidates (aCSHR = 0.48 0.58 0.69, p<0.001). Post-implementation, 
access to DDLT was substantially reduced for HCC candidates compared to non-HCC 
candidates after adjustment. HCC candidates had 73% lower access to DDLT compared to 
non-HCC candidates (aCSHR = 0.18 0.27 0.40, p<0.001). The difference in pre- and post-
implementation association between HCC and access to DDLT was statistically significant 




HCC, DDLT, and waitlist mortality/dropout pre- and post-implementation 
After taking into account the fact that transplantation precludes waitlist mortality/dropout, 
HCC candidates were at higher risk of waitlist mortality/dropout compared to non-HCC 
candidates when adjusting for age, gender, race, and calculated MELD. Pre-
implementation, the risk of waitlist mortality/dropout was 1.30 fold higher for HCC 
candidates compared to non-HCC candidates (asHR = 1.151.30 1.46, p<0.001). Post-
implementation, the risk of waitlist mortality/dropout for HCC candidates increased further 
up to 2.18 folds higher compared to non-HCC candidates (asHR = 1.69 2.18 2.80, p<0.001). 
The difference in pre- and post-implementation association between HCC and waitlist 
mortality/dropout was statistically significant (interaction p<0.001) (Table 4).  
 
Age >50 years (asHR = 1.75 1.93 2.12, p<0.001), female gender (asHR = 1.06 1.15 1.24, 
p<0.001) and 5 point increase in calculated MELD score (asHR = 1.69 1.72 1.75, p<0.001) 
were identified as risk factors for increased risk of waitlist mortality/dropout. White and 
Hispanic candidates had similar risks of waitlist mortality/dropout (asHR= 0.88 0.97 1.07, 
p>0.1). Black and those of other race had 23% (asHR = 0.66 0.77 0.89, p<0.001) and 20% 
(asHR=0.67 0.80 0.96, p=.017) lower risks of waitlist mortality/dropout compared to white 
respectively (Table 4).  
 
HCC, DDLT, and waitlist mortality/dropout across MELD strata 
Calculated MELD 6-10: Within this stratum, the risk of waitlist mortality/dropout was 39% 
higher among HCC candidates compared to non-HCC candidates in the pre-
implementation era (asHR = 1.01 1.39 1.92, p=0.046) Post-implementation, HCC and non-
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HCC candidates had comparable risks of waitlist mortality/dropout (asHR = 0.18 0.53 1.54, 
p>0.1) (Table 5). The difference in pre- and post-implementation association between HCC 
and risk of waitlist mortality/dropout was not statistically significant (interaction p=0.08)  
 
Calculated MELD 11-18: Pre-implementation, HCC and non-HCC candidates had 
comparable risks of waitlist mortality/dropout (asHR = 0.98 1.18 1.43, p=0.08). Post-
implementation, HCC candidates had 1.71 times higher risks of waitlist mortality/dropout 
compared to non-HCC candidates (asHR = 1.02 1.71 2.86, p=0.04) (Table 5). The difference 
in pre- and post-implementation association between HCC and risk of waitlist 
mortality/dropout was not statistically significant (interaction p-value >0.1).  
 
Calculated MELD 19-24: Pre-implementation, the risk of waitlist mortality/dropout for 
HCC candidates was 1.64 folds higher (asHR = 1.27 1.64 2.11, p<0.001) compared to non-
HCC candidates. Risk of waitlist mortality/dropout increased to 1.82 fold among HCC 
candidates compared to non-HCC candidates post-implementation (asHR = 1.02 1.82 3.25, 
p=0.04). The difference in pre- and post-implementation association between HCC and 
risk of waitlist mortality/dropout was not statistically significant (interaction p-value >0.1) 
(Table 5). 
 
Calculated MELD 25-40: Pre-implementation, the risk of waitlist mortality/dropout for 
HCC candidates was found to be 1.31 fold higher than that for non-HCC candidates (asHR 
= 1.08 1.31 1.58, p<0.01). Post-implementation, the risk of waitlist mortality/dropout 
increased to 3.11 fold higher for HCC candidates compared to non-HCC candidates (asHR 
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= 2.19 3.11 4.42, p<0.001). The difference in pre- and post-implementation association 






 DISCUSSION  
 
In this study of access to DDLT among HCC and non-HCC candidates before and after the 
October 2015 policy change regarding MELD exception points for HCC candidates, we 
found that, compared to non-HCC candidates, HCC candidates had higher access to DDLT 
in the pre-implementation period. However, in the post-implementation period, HCC and 
non-HCC candidates had similar access to DDLT. Additionally, the risk of waitlist 
mortality/dropout for HCC candidates increased from 1.3-fold in the pre-implementation 
era to 2.18-fold in the post-implementation period compared to non-HCC candidates.  
 
We found that, in the pre-implementation period, HCC candidates had a higher rate of 
DDLT compared to non-HCC candidates. Previous studies by Washburn et al. and Goldber 
et al. found that the current liver allocation system favors HCC candidates over non-HCC 
candidates, as evidenced by the lower rate of waitlist mortality/dropout among HCC 
candidates (32, 33). Northup et al. also reported similar findings, indicating a higher rate 
of DDLT and lower rate of waitlist mortality/dropout for candidates with exception points, 
such as HCC candidates (34). Our current study showed that these disparities between HCC 
and non-HCC candidates with regards to the rates of DDLT and waitlist mortality/dropout 
persisted until the October 2015 MELD exception point policy change. Our group also 
previously used 2002-2010 OPTN data to describe these disparities, finding that HCC 
candidates were advantaged with regards to DDLT organ allocation in the pre-
implementation period as compared to non-HCC candidates (36). The present study 
extends our prior work by reporting the rate of DDLT across strata of calculated MELD, 
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and by comparing rates of DDLT in the pre-implementation and post-implementation 
periods.  
 
We reported that HCC and non-HCC candidates had similar access to DDLT in the post-
implementation period. Two studies have previously predicted a reduced disparity in 
access to DDLT between HCC and non-HCC candidates accounting for the 6 month delay 
in exception point allocation using UNOS data from the pre-implementation period (46, 
47). Applying liver simulation allocation modeling (LSAM) on waitlisted candidates from 
the year 2010, Heimbach et al. predicted that a 6 month delay in exception point allocation 
would diminish the disparity in access to DDLT between HCC and non-HCC candidates 
(44.2 vs. 33.9 per 100 person-years) (46). Similarly, Alver et al. used 2009-2014 UNOS 
data to construct a non-parametric multistate model for predicting probabilities of 
transplant and waitlist mortality/dropout for HCC and non-HCC candidates in both the pre-
implementation and post-implementation eras. In this study, Alver et al. reported lower 
access to DDLT for HCC candidates compared to non-HCC candidates (8.2% vs. 41.2%) 
at   6 months and  improved equity at 1 year (45.9% vs. 46.8%). Our study findings are 
consistent with these predictions, demonstrating that the overall rate of DDLT was similar 
between HCC and non-HCC candidates during the post-implementation period (aCSHR = 
0.81 0.93 1.07). However, in the same study, Alver et al. also predicted that this improved 
equity in access to DDLT among HCC and non-HCC candidates would subsequently 
diminish after 1 year, again resulting in an advantage for HCC candidates compared to 
non-HCC candidates (70.2% vs. 50.1% at 18 month, 78.3% vs. 52.2% at 24 month and 
83.8% vs. 54.9% at 36 months) (47). Since our study is limited to only the first 8 months 
25 
 
post-implementation, further studies are needed to investigate the equity in transplant rate 
between HCC and non- HCC candidates after 6 month.  
 
In a recent study, Marvin et al. used 2005-2009 UNOS data to predict the probabilities of 
waitlist mortality/dropout and transplantation considering the six month delay in exception 
point allocation (48). Using multistate models in different strata of an alternative MELD 
score named equivalent MELD (MELDEQ = max[MELDCALQ-EQ, calculated MELD]), in 
which MELDCALQ-EQ was determined by equating the hazards of waitlist dropout for HCC 
and non-HCC candidates based on other covariates and their calculated MELD scores, 
Marvin et al. reported an increased risk of waitlist mortality/dropout among HCC 
candidates with higher MELDEQ versus a decreased risk of waitlist mortality/dropout 
among HCC candidates with lower MELDEQ (48). The results of our study extend Marvin 
et al.’s findings by showing that this relationship holds in the post-implementation era and 
after accounting for the competing risk of transplantation. Furthermore, our finding that, in 
the post-implementation period, HCC candidates in higher MELD strata (19-24, 25-40) 
had a lower rate of DDLT and a higher risk of waitlist mortality/dropout bolsters Marvin 
et al.’s case that an improved system is needed for prioritizing HCC patients with higher 
calculated MELD (48). 
 
Our study must be understood in the context of several limitations. Due to concerns about 
potential reporting bias we are only able to study waitlist mortality/dropout for the first 8 
months following the October 2015 exception point policy change. Thus, it remains 
uncertain whether the patterns we identified will persist. We also recognize the potential 
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limitations of using registry-based data. OPTN data are gathered across hundreds of 
centers, potentially with varying degrees of quality control and different policies for 
checking and updating MELD scores. Additionally, we adjusted for a limited number of 
covariates based on what factors were available in this database; for instance, we were 
unable to adjust for factors such as pre-transplant HCC treatment as such covariates were 
not available in our data. However, despite these limitations, national registries constitute 
the only comprehensive data source for studies of changes in organ allocation at the 
national level.  
 
Despite the aforementioned limitations, our study also has several key strengths. To our 
knowledge, this is the first study of changes in rates of DDLT and risk of waitlist 
mortality/dropout in light of recent changes to the policy regarding exception point 
allocation for HCC liver transplant candidates. The sample size of our study was large 
enough to provide sufficient power in the stratified analysis. Other strengths include 
accounting for the dynamic nature of MELD, and the use of competing risks methods to 
elucidate the relationship between allocation priority and waitlist mortality/dropout. 
 
In conclusion, our findings from this national registry-based study of access to DDLT 
among HCC and non-HCC transplant candidates suggest that post implementation of the 
October 2015 MELD exception point allocation policy, the disparity in access to DDLT 
among HCC and non-HCC candidates was eliminated while the risk of waitlist 
mortality/dropout increased almost 2-fold for HCC candidates compared to non-HCC 
candidates. The relationship between HCC and rate of DDLT varied across different strata 
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of calculated MELD in both the pre- and post-implementation periods. In lower MELD 
strata (6-10, 11-18), discrimination regarding organ allocation between HCC and non-HCC 
candidates was reduced post-implementation, however the risk of waitlist 
mortality/dropout did not change. In higher MELD strata (19-24, 25-40), there was 
decreased access to DDLT for HCC candidates in the post-implementation period along 
with a corresponding increase in the risk of waitlist mortality/dropout for HCC candidates 
compared to non-HCC candidates. 
 
Further research is needed to explore post-transplant outcomes for HCC candidates who 
had a 6 month delay in getting their first exception point. Additional investigation is also 
necessary to explore geographic disparity in access to DDLT under the new policy since 
several studies reported about existing geographic disparity in liver allocation (49, 50)..  
 
Our study findings show that after the policy change, there was a reducion in disparity 
between HCC and non-HCC candidates within lower calculated MELD strata (6-10, 11-
18). However,  under the new policy, HCC candidates within higher calculated MELD 
strata (19-24, 25-40) also had lower access to DDLT. Therefore, revision to the exception 






Table 1: Modification of standardized exception score from 2002-2015 
 





































(78.6%) 2084 (26.8%) 5691 (73.2%) 
Median Age (IQR) age 
61 (57-
65) 
57 (50-62) 61 (57-65) 56 (48--62) 
Female (%) 23.6 40.3 24.0 40.8 
Race     
White (%) 63.3 72.4 64.3 71.9 
Black (%) 10.1 7.5 9.3 7.3 
Hispanic/Latino (%) 17.2 15.4 18.1 15.7 
Other (%) 9.3 4.6 8.2 4.8 
Blood group type (%)     
O 47.3 46.5 46.8 47.0 
A 37.1 38.6 36.8 36.8 
B 12.5 12.1 12.9 12.2 
AB 2.9 2.7 3.3 3.9 
Median (IQR) 
calculated MELD  
10 (8-14) 15 (11-20) 10 (8-14) 19 (14-26) 
Median (IQR) 
allocation MELD  
22 (22-
25) 
16 (11-22) 11 (8-15) 20 (15-28) 
Primary Diagnosis (%)     
Hepatoma 12.1 0 10.7 0 
Hepatoma with 
cirrhosis 
19.5 0 21.9 0 
Cirrhosis with 
Hepatitis C 
39.6 22.4 35.9 13.1 
Cirrhosis with 
Hepatitis B 
3.3 1.8 2.5 1.6 
Alcoholic cirrhosis 
with/without  Hepatitis 
C 
11.7 30.3 12.9 33.7 
Fatty liver 6.1 15.3 8.8 20.2 
Cryptogenic 1.6 6.3 1.9 6.0 
Autoimmune 0.8 4.1 0.4 4.2 




Table 3. DDLT candidate characteristics associated with access to DDLT, regardless of 

















 0.61 0.71 0.83 























































p-value for HCC and policy intercation <0.001 <0.001 




Table 4. DDLT candidate characteristics associated with waitlist mortality/dropout, 
regardless of access to DDLT (Cox) and accounting for access to DDLT as a competing 
risk (CR) 
 










 1.69 2.18 2.80 








































p-value for HCC and policy intercation 0.8 <0.001 





Table 5. Access to DDLT and waitlist mortality/dropout,    pre- & post implementation 
across MELD strata   HCC candidate’s pre- and post-policy change 
 
 DDLT rate: HCC vs non-HCC Waitlist mortality/dropout  
accounting for competing risk of 





























































































Figure 2. Cumulative incidence of DDLT for HCC and non-HCC candidates, treating 
waitlist mortality/dropout as a competing risk.  Pre-implementation, cumulative incidence 
of transplantation was substantially higher for HCC candidates than for non-HCC 












Figure 3. Access to DDLT for HCC and non-HCC candidates, pre-implementation, 
across MELD strata, treating waitlist mortality/dropout as a competing risk.  Cumulative 
incidence of transplantation was substantially higher for HCC candidates than for non-








Figure 4. Access to DDLT for HCC and non-HCC candidates, post-implementation, 
stratified by MELD strata, treating waitlist mortality/dropout as a competing risk.  
Cumulative incidence of transplantation was similar for HCC and non-HCC candidates in 
MELD strata 6-10 & 11-18 but lower for HCC candidates compared to non-HCC 







Figure 5: Waitlist mortality/dropout risk for HCC and non-HCC candidates, treating access 
to DDLT as a competing risk.  Among all waitlist candidates, cumulative incidence of 
waitlist mortality/dropout was slightly higher for non-HCC candidates than for HCC 









Figure 6. Waitlist mortality/dropout risk for HCC and non-HCC candidates, pre-
implementation, stratified by calculated MELD, treating access to DDLT as a competing 
risk across MELD strata (Pre-implementation era). Cumulative incidence of 
mortality/dropout was similar for HCC and non-HCC candidates in MELD strata 6-10 & 
11-18 but slightly higher for HCC candidates than for non-HCC candidates in MELD strata 








Figure 7. Waitlist mortality/dropout risk for HCC and non-HCC candidates, post-
implementation, stratified by calculated MELD, treating access to DDLT as a competing 
risk across MELD strata (Pre-implementation era). Cumulative incidence of 
mortality/dropout was similar for HCC and non-HCC candidates in MELD strata 6-10 & 
11-18 but slightly higher for HCC candidates than for non-HCC candidates in MELD 
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